

CONTENTS

FOREWORD	xi
<i>Joy A. Cavagnaro, PhD, DABT, RAC, and Anthony D. Dayan, LLB, MD, FRCP, FRCPath, FFOM, FFPM, FIBiol</i>	
ACKNOWLEDGMENTS	xix
CONTRIBUTORS	xxi
PART I BACKGROUND	1
1. Biopharmaceuticals: Definition and Regulation	3
<i>Lincoln Tsang, PhD, FRSC, FIBiol, FRPharmS (Arnold and Porter, London, UK), and Nathan Cortez (Southern Methodist University)</i>	
2. Methods of Production of Biopharmaceutical Products and Assessment of Environmental Impact	21
<i>Patricia D. Williams, PhD (Summit Drug Development Services)</i>	
PART II PRINCIPLES OF PRECLINICAL DEVELOPMENT	43
3. The Principles of ICH S6 and the Case-by-Case Approach	45
<i>Joy A. Cavagnaro, PhD, DABT, RAC (Access BIO)</i>	
4. Implementation of ICH S6: EU Perspective	67
<i>Peter R. Ryle, PhD, DipRCPath (Tox), FRCPath (PR BioServices), and David J. Snodin, PhD, FRSC, MChemA, MSc (Parexel Consulting)</i>	
5. Implementation of ICH S6: Japanese Perspective	93
<i>Takahiro Nakazawa, PhD (Eli Lilly Japan)</i>	
6. Implementation of ICH S6: US Perspective	111
<i>Mary Ellen Cosenza, PhD, MS, DABT, RAC (Amgen)</i>	

PART III CURRENT PRACTICES IN PRECLINICAL DEVELOPMENT	123
7. Comparison of Preclinical Development Programs for Small Molecules (Drugs/Pharmaceuticals) and Large Molecules (Biologics/Biopharmaceuticals): Studies, Timing, Materials, and Costs	125
<i>Christopher Horvath, DVM, MS, DACVP (Archemix Corp.)</i>	
8. Demonstration of Comparability of a Licensed Product after a Manufacturing Change	161
<i>Richard M. Lewis, PhD (Access BIO)</i>	
PART IV SELECTION OF RELEVANT SPECIES	179
9. Selection of Relevant Species	181
<i>Meena Subramanyam, PhD, Nicola Rinaldi, PhD, Elisabeth Mertsching, PhD, and David Hutto, PhD, DVM (Biogen Idec)</i>	
10. Tissue Cross-Reactivity Studies for Monoclonal Antibodies: Predictive Value and Use for Selection of Relevant Animal Species for Toxicity Testing	207
<i>William C. Hall, VMD, PhD, DACVP (Hall Consulting Inc.), Shari A. Price-Schiavi, PhD, DABT (Charles River Laboratories—PAI), Joan Wicks, DVM, PhD, DACVP (Charles River Laboratories—PAI), and Jennifer L. Rojko, DVM, PhD, DACVP (Charles River Laboratories—PAI)</i>	
11. Physiologic IgG Biodistribution, Transport, and Clearance: Implications for Monoclonal Antibody Products	241
<i>Jennifer L. Rojko, DVM, PhD, DACVP, and Shari Price-Schiavi, PhD, DABT (Charles River Laboratories—PAI)</i>	
12. The Role of Pharmacokinetics and Pharmacodynamics in Selecting a Relevant Species	277
<i>Martin D. Green, PhD (FDA), and Melanie Hartsough, PhD (Biologics Consulting Group, Inc.)</i>	
13. Use of Animal Models of Disease in the Preclinical Safety Evaluation of Biopharmaceuticals	293
<i>Johan te Koppele, PhD (TNO Quality of Life) and Renger Witkamp, PhD (Wageningen University, The Netherlands)</i>	

PART V SAFETY/TOXICITY ENDPOINTS	309
14. Safety Pharmacology: Similarities and Differences between Small Molecules and Novel Biopharmaceuticals	311
<i>Edward W. Bernton, MD (Pathway Pharmacology)</i>	
15. Genetic Toxicology Testing of Biopharmaceuticals	337
<i>David Jacobson-Kram, PhD, DABT, and Hanan Ghantous, PhD, DABT (FDA)</i>	
16. General Toxicity Testing and Immunotoxicity Testing for Biopharmaceuticals	343
<i>Jeanine L. Bussiere, PhD, DABT (Amgen)</i>	
17. Reproductive Toxicity Testing for Biopharmaceuticals	357
<i>Pauline L. Martin, PhD (Centocor Research and Development Inc.)</i>	
18. Reproductive/Developmental Toxicity Assessment of Biopharmaceuticals in Nonhuman Primates	379
<i>Gerhard F. Weinbauer, PhD, Werner Frings, PhD, Antje Fuchs, PhD, Michael Niehaus, PhD, and Ingrid Osterburg (Covance, Germany)</i>	
19. Preclinical Evaluation of Cancer Hazard and Risk of Biopharmaceuticals	399
<i>Joy A. Cavagnaro, PhD, DABT, RAC (Access BIO)</i>	
20. Immunogenicity of Therapeutic Proteins and the Assessment of Risk	475
<i>Huub Schellekens, MD, PhD (Utrecht University), and Wim Jiskoot, PhD (Leiden University)</i>	
21. Assessment of Autoimmunity and Hypersensitivity	487
<i>Jacques Descotes, MD, PharmD, PhD, and Thierry Vial, MD (Poison Centre and Pharmacovigilance Unit, Lyon, France)</i>	
PART VI SPECIFIC CONSIDERATIONS BASED ON PRODUCT CLASS	499
22. Current Practices in the Preclinical Safety Assessment of Peptides	501
<i>Shawn M. Heidel, DVM, PhD, and Todd J. Page, PhD (Eli Lilly)</i>	
23. Enzyme Replacement Therapies	517
<i>Laura Andrews, PhD, DABT (Genzyme), and Michael O'Callaghan, DVM, PhD, MRCVS (Genzyme)</i>	

- 24. Toxicology of Oligonucleotide Therapeutics and Understanding the Relevance of the Toxicities** 537
Arthur A. Levin, PhD, DABT (Biotech & Pharmaceutical Consulting), and Scott P. Henry, PhD, DABT (Isis)
- 25. Preclinical Safety Evaluation of Biological Oncology Drugs** 575
Theresa Reynolds, BA, DABT (Genentech)
- 26. Preclinical Safety Evaluation of Monoclonal Antibodies** 587
George Treacy, MS, and Pauline Martin, PhD (Centocor Research and Development)
- 27. Immunomodulatory Biopharmaceuticals and Risk of Neoplasia** 601
Peter J. Bugelski, PhD, FRCPath, Clifford Sachs, PhD, DABT, Joel Cornacoff, DVM, PhD, DABT, Pauline Martin, PhD, and George Treacy, MS (Centocor Research and Development)
- 28. Strategy Considerations for Developing the Preclinical Safety Testing Programs for Protein Scaffold Therapeutics** 633
Stanley A. Roberts, PhD, DABT, Gary Woodnutt, PhD, and Curt W. Bradshaw, PhD (CovX Research, LLC)
- 29. Preclinical Safety Evaluation of Immunotoxins** 649
Jennifer G. Brown, PhD, Joycelyn Entwistle, PhD, Nick Glover, PhD, and Glen C. MacDonald, PhD (Viventia Biotech, Inc)
- 30. Preclinical Safety Evaluation of Blood Products** 669
Richard M. Lewis, PhD (Access BIO)
- 31. Preclinical Safety Evaluation of Viral Vaccines** 683
A. Marguerite Dempster, PhD, DABT, and Richard Haworth, FRCPath, DPhil (GlaxoSmithKline)
- 32. Preclinical Safety Evaluation of Biopharmaceuticals** 713
Mercedes A. Serabian, MS, DABT, and Ying Huang, PhD (FDA)
- 33. Considerations in Design of Preclinical Safety Evaluation Programs to Support Human Cell-Based Therapies** 749
Joy A. Cavagnaro, PhD, DABT, RAC (Access BIO)
- 34. Preclinical Safety Evaluation of Biopharmaceuticals: Combination Products (Biologic/Device)** 783
Bruce Babbitt, PhD, and Barry Sall (Parexel Consulting)
- 35. Tissue Engineered Products: Preclinical Development of Neo-Organs** 799
Timothy A. Bertram, DVM, PhD, and Manuel Jayo, DVM, PhD (Tengion)

PART VII PRECLINICAL STUDY DESIGN, IMPLEMENTATION, AND ANALYSIS	827
36. GLP Requirements and Current Practices <i>Tanya Scharton-Kersten (Novartis)</i>	829
37. Preclinical Safety Study Design Templates and Estimated Costs <i>Gary W. Wolfe, PhD, DABT (Summit Drug Development Services)</i>	851
38. Practical Considerations in the Design of Preclinical Safety Assessments for Biopharmaceuticals <i>Damon R. Demady, PhD (Knopp Neurosciences)</i>	913
39. Survey of Preclinical Toxicology Programs for Approved Biopharmaceuticals <i>Anita Marie O'Connor, PhD (Anita O'Connor Consulting, LLC)</i>	931
PART VIII TRANSITIONING FROM PRECLINICAL DEVELOPMENT TO CLINICAL TRIALS	969
40. Science and Judgment in Establishing a Safe Starting Dose for First-in-Human Trials of Biopharmaceuticals <i>Jennifer Visich, PhD (Genentech), and Rafael Ponce, PhD, DABT (Zymogenetics)</i>	971
PART IX AFTERWORD	985
A Retrospective <i>Anthony D. Dayan, LLB, MD, FRCP, FRCPath, FFOM, FFPM, FIBiol</i>	987
INDEX	999

